Table 4.
Association of KIT mutations with prognostic factors in CBF-AML.
| Variable | Pediatrics |
Adults |
||||
|---|---|---|---|---|---|---|
| KIT negative N = 29 | KIT positive N = 5 | p value | KIT negative N = 27 | KIT positive N = 8 | p- value | |
| Sex | ||||||
| Male: n (%) | 16(55.2) | 5(100) | 14(51.9) | 5(62.5) | ||
| Female: n (%) | 13(44.8) | 0.132 | 13(41.8) | 3(37.5) | 0.700 | |
| FAB subtypes | ||||||
| M1 + M2 | 18(62.1) | 3(60) | 16(59.3) | 6(75) | ||
| M4 + M5 | 11(37.9) | 2(40) | 1.000 | 11(40.7) | 2(25) | 0.683 |
| Hepatomegaly | ||||||
| negative: n (%) | 21(72.4) | 3(60) | 20(74.1) | 4(50) | ||
| positive: n (%) | 8(27.6) | 2(40) | 0.678 | 7(25.9) | 4(50) | 0.226 |
| Splenomegaly | ||||||
| negative: n (%) | 24(82.8) | 4(80) | 22(81.5) | 4(50) | ||
| positive: n (%) | 5(17.2) | 1(20) | 1.000 | 5(18.5) | 4(50) | 0.162 |
| Lymphadenopathy | ||||||
| negative: n (%) | 27(93.1) | 5(100) | 2(7.4) | 1(12.5) | ||
| positive: n (%) | 2(6.9) | 1.000 | 2(7.4) | 1(12.5) | 0.553 | |
| t(8:21) | ||||||
| t(8:21) negative | 10(34.5) | 2(40) | 11(40.7) | 2(25) | ||
| t(8:21) positive | 19(65.5) | 3(60) | 1.000 | 16(59.3) | 6(75) | 0.680 |
| Inv (16) | ||||||
| Inv16 wild | 19(65.5) | 3(60) | 16(59.3) | 6(75) | ||
| Inv 16 positive | 10(34.5) | 2(40) | 1.000 | 11(40.7) | 2(25) | 0.680 |
| FLT3- ITD | ||||||
| FLT3 ITD wild | 28(69.6) | 5(100) | 25(92.6) | 8(100) | ||
| FLT3 ITD mutant | 1(3.4) | 0 | 1.000 | 2(7.4) | 0 | 1.000 |
| FT3- TKD | ||||||
| FLT3 TKD wild | 28(69.6) | 5(100) | 25(92.6) | 7(87.5) | ||
| FLT3 TKD mutant | 1(3.4) | 0 | 1.000 | 2(7.4) | 1(12.5) | 0.553 |
| HGB (g/dL) | ||||||
| ≤ 8 g/dl | 21(72.4) | 3(60) | 16(59.3) | 4(50) | ||
| > 8 g/dl | 10(34.5) | 2(40) | 0.618 | 11(40.7) | 4(50) | 0.700 |
| PLT (x109/L) | ||||||
| < = 20 × 109/L | 8(27.6) | 2(40) | 8(29.6) | 4(50) | ||
| > 20 × 109/L | 8(27.6) | 2(40) | 0.618 | 8(29.6) | 4(50) | 0.402 |
| TLC (x109/L) | ||||||
| < 20,000 | 10(34.5) | 2(40) | 16(59.3) | 5(62.5) | ||
| > 20 × 109/L | 19(65.5) | 3(60) | 1.000 | 11(40.7) | 3(37.5) | 1.000 |
| Pb Blast (%) | ||||||
| Mean ± SD | 34.483 ± 18.13 | 43.2 ± 19.52 | 0.392 | 38.47 ± 25.5 | 34.12 ± 17.36 | 0.558 |
| BM Blast (%) | ||||||
| Mean ± SD | 50.65 ± 20.03 | 55.2 ± 24.87 | 0.715 | 51.074 ± 24.21 | 60.62 ± 22.66 | 0.323 |
| Response to induction chemotherapy | ||||||
| CR | 15(56.2) | 1(33.3) | 13(68.4) | 2(28.6) | ||
| RD | 8(34.8) | 2(66.7) | 1.000 | 6(31.6) | 5(71.4) | 1.000 |
Data are presented as n (%). FAB: French-American-British classification, FLT3 ITD: Fms-like Tyrosine Kinase Internal Tandem Duplication, FLT3 TKD: Fms-like Tyrosine Kinase Tyrosine Kinase Domain, HGB: Hemoglobin, PLT: Platelets count, TLC: Total Leukocyte Count, PB Blast: Peripheral Blood Blast, BM Bone marrow blasts. CR: Complete Remission, RD: Resistant Disease, OS: Overall survival.